The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Invasive mediastinal re-staging after neoadjuvant therapy in NSCLC
Paul van Schil, MD, PhD, University Hospital Antwerp, Antwerp, Belgium, emphasizes the importance of restaging the mediastinum after neoadjuvant therapy for non-small cell lung cancer (NSCLC), particularly for patients with persistent N2 disease. This approach can significantly improve patient outcomes, as evidenced by studies from earlier trials such as EORTC 08941 (NCT00002623) and Intergroup 0139, and suggests that radiotherapy may be a more effective treatment option than surgical resection for patients with persistent N2 disease. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
